Clinical Trial

A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

Study acronym: GREVIT
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).
Trial Details
NCT Number NCT07647237
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Vitiligo
Enrollment 116 participants
Start Date 2026-06
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-15